The long term anticoagulation with warfarin is associated with various bleeding risks which led to the need for newer drugs. With the developments in the anticoagulation therapy the newer agents like dabigatran, rivaroxaba, apixaban and edoxaban have gained popularity with their more predictable pharmacological properties and reduced need for drug monitoring.The United States of America has approved both rivaroxaban and dabigatran to be used in the treatment of VTE (Venous Thrombo Embolism). In Europe and Canada dabigatran is prescribed after elective hip or knee arthroplasty to prevent VTE. For a VTE prophylaxis after an orthopediac surgery and to prevent stroke in AF patient, Rivaroxaban is recommended according to RECORD study. Edoxaban is highly effective in treatment of VTE and acts as a preventive measure of stroke in NVAF (Nonvalvular Atrial Fibrillation). Through this article various pharmacological aspects, dosing regimens, bleeding associated risk will be illustrated.